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Background
On January 14, 2005 the FDA Nonprescription
and Endocrinologic & Metabolic Drugs Advisory
Committees voted against the OTC marketing of
lovastatin 20 mg (Mevacor Daily). This follows a
similar denial by the committees in July 2000
when lovastatin 10 mg was proposed for OTC
consideration.1

The United Kingdom Model
The model for OTC statin status was set in the
United Kingdom (U.K.) with the approval of lowdose Zocor Heart-Pro (simvastatin) this past July
2004. Zocor Heart-Pro 10 mg is available in a
“behind the counter” status. These restricted OTC
products require patient-pharmacist interaction
prior to the pharmacist providing the statin to a
U.K. consumer.2 A similar process for the
American Pharmacists Association’s (APhA’s)
“Pharmacy Care OTCs” would include product
placement and promotion requiring direct
consumer-pharmacist interaction with supporting
written information and guidance documents.
Included in these activities are disease-risk
assessment and monitoring.3,4
In the U.K., simvastatin is considered suitable
for patients with moderate risk of coronary heart
disease. Those individuals include men 55 to 70
with or without risk factors, men 45 to 54 with
one or more risk factors, and post-menopausal
women 55 to 70 with one or more listed risk
factors. The risk factors include smokers, family
history of early heart disease, being overweight or
obese, and those of south Asian family origin.
Their practice guidance document states that it is
not necessary to have a patient’s cholesterol status
to identify them as being at moderate risk and that
it is possible to determine moderate risk through
an individual’s self-reported risk factors. It is
suggested that a cholesterol test is a good practice
as a baseline prior to therapy and then at least
yearly thereafter. Blood pressure measurement is

not a required practice prior to starting therapy but
is recommended. Liver function testing is not
required. Pharmacists should be involved in the
initial sales of simvastatin including discussion of
risk factors, healthy lifestyle, contraindications,
cautions, adverse effects, and drug interactions.
Record keeping of sales and discussions is
recommended.5
Prior to and after statin OTC status approval in
the U.K., there were supporting and opposing
comments, some of which were politically based.
Others were related to the absence of clinical trials
with the 10 mg dose of simvastatin and no trials in
an OTC population. Concern was also expressed
that OTC statin presence would reduce healthy
lifestyle changes. A positive primary preventative
measure is that the target population is below the
threshold at which the National Health Service
provides prescription statin therapy.6

The U.S. Decision
The FDA Nonprescription and Endocrinologic
& Metabolic Drugs Advisory Committees’
decision to reject Mevacor Daily’s OTC status
and the immediate potential for any other OTC
statin’s emergence, was based on the committees’
opinion that patients would have difficulty in the
treatment self-selection process and potential
inability to comply with long-term use and testing.
Members described that the current OTC system
is not adequate for this level of patient
responsibility. Many further indicated that they
would have voted in favor of the OTC status if a
“behind-the-counter” system as in the U.K. were
available. This was an undeclared vote in favor of
APhA’s Pharmacy Care OTC proposal.
Additional concerns were expressed relative to
fetal risks associated with statins which carry a
category X classification.7 This concern was
evidenced by the committees lack of support for
the self-diagnosis results of the Merck-sponsored
study: A Consumer Use Study of Over-theMore. . .
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Counter Lovastatin (CUSTOM).1,8 They felt that
the study did not adequately demonstrate
lovastatin safety and efficacy in the OTC setting.
The CUSTOM study’s target population was
individuals with LDL-cholesterol in the 130 to
170 mg/dL range. It was a consumer driven and
self-selection study open to consumers in an
uncontrolled manner. Participants self-selected
and self-deselected themselves based on written
guidelines and OTC Mevacor labeling. The study
evaluated the ability of participants to self-manage
their therapy without pharmacist or other health
care professional involvement.
The OTC
Mevacor-consumer study demonstrated that the
participants could appropriately self-select and
self-manage their cholesterol over time. Despite
the study authors’ conclusions, the FDA
committees did not feel that there was sufficient
safety in this self-guided approach.1,8,9

Pharmacy Care OTCs: A New Drug Class
The CUSTOM study proposed a simulated
OTC model for statins. It was limited to a selfselected population, did not evaluate clinical
outcomes, and therefore did not demonstrate
efficacy.8 Ultimately, it was not supported.1
Statins are an ideal drug category for
consideration as a new drug class model. The
APhA’s Pharmacy Care OTC model new drug
class provisions provide the necessary safety and
efficacy “frame” for statins. This OTC model
would fulfill the need to identify appropriate
candidates for statin therapy.
Risk factor
identification, family, medical, and concomitant
therapy history, lifestyle and therapeutic
education, adverse event prevention, and
monitoring of treatment response for best
outcomes would occur with the direct health care
professional interaction proposed.
Primary
prevention of cardiovascular events in patients
without known CHD could be achieved for a
greater percent of the population.
Changes in U.S. federal statutes and
regulations would be necessary to establish this
new non-prescription drug class available only
from pharmacists and other licensed health care
professionals.10
Alternately, OTC statins could be marketed as
any other OTC product, as was proposed by
Merck for their Mevacor Daily product, with
appropriate consumer labeling and guidance
documents. Furthermore, manufacturers could

label their proposed-statin OTC products with
“behind-the-counter” storage requirements and
suggested
health
care
professional
recommendations.10
In Canada, the National Association of
Pharmacy Regulatory Authorities has a
scheduling system for classification of
medications.
Schedule I drugs require a
prescription. Schedule II therapies (“pharmacist
only”) may be purchased over-the-counter but are
stored in a non-public access area in the pharmacy
and require professional intervention by a
pharmacist at the point of sale. Insulin and iron
products with more than 30 mg elemental iron per
dosage form are examples. A third restricted
OTC category, Schedule III (“pharmacy only”), is
available only in a pharmacy so that the consumer
may ask questions of the pharmacist. The
pharmacist assists the patient in selecting these
medications. Examples include Advil (ibuprofen)
400 mg and Benadryl (diphenhydramine) 50 mg.
With this drug scheduling system available in
Canada, OTC statin placement will be favorable.11
Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.
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